MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)。

Tacrolimus

CAS No. : 104987-11-3

MCE 國(guó)際站：Tacrolimus

產(chǎn)品活性：Tacrolimus (FK506)，大環(huán)內(nèi)酯類(lèi)，與 FK506 結(jié)合蛋白 (FKBP) 結(jié)合形成復(fù)合物并抑制鈣調(diào)神經(jīng)磷酸酶 (calcineurin phosphatase)，從而抑制 T 淋巴細(xì)胞信號(hào)轉(zhuǎn)導(dǎo)和 IL-2 轉(zhuǎn)錄。具有強(qiáng)免疫抑制特性。

研究領(lǐng)域：Metabolic Enzyme/Protease  |  Autophagy  |  Apoptosis  |  Immunology/Inflammation  |  Anti-infection

作用靶點(diǎn)：Phosphatase  |  FKBP  |  Bacterial  |  Autophagy  |  Antibiotic

結(jié)構(gòu)分類(lèi)：抗生素  |  疾病研究  |  抗炎/免疫調(diào)劑  |  抗生素  |  大環(huán)內(nèi)脂類(lèi)  |  結(jié)構(gòu)分類(lèi)

In Vitro: Tacrolimus (FK506) inhibits calcium-dependent events, such as IL-2 gene transcription, NO synthase activation, cell degranulation, and apoptosis. Tacrolimus also potentiates the actions of glucocorticoids and progesterone by binding to FKBPs contained within the hormone receptor complex, preventing degradation. The agent may enhance expression of the TGFβ-1 gene in a fashion analogous to that demonstrated for CsA. T cell proliferation in response to ligation of the T cell receptor is inhibited by Tacrolimus. Treatment with a low concentration of Tacrolimus (FK506,10 μg/L) does not significantly affect the proliferation of MH3924A cells (P=0.135). Upon treatment with higher concentrations of Tacrolimus (100-1,000 μg/L), the proliferation of MH3924A cells is significantly enhanced (P<0.01). Treatment with AMD3100 at any concentration (10, 50 or 100 μg/L), has no obvious effect on MH3924A cell proliferation (P>0.05). However, when different concentrations of AMD3100 are combined with 100 μg/L Tacrolimus, the in vitro proliferation of MH3924A cells is increased (P<0.01).

In Vivo: The therapeutic effect of Tacrolimus is investigated on progression and perpetuation of colitis by administering Tacrolimus to Dextran sulfate sodium (DSS)-treated mice from Days 10 to 16 or to 23. At Days 17 and 24, colon length is significantly shortened, and colon weight is significantly higher in DSS-treated control animals than in normal animals. In addition, colon weight per unit length in the control group is more than twice that in the normal group. While both 7 and 14 d treatment with Tacrolimus significantly suppresses increases in colon weight per unit length in DSS-treated animals compared with the control group, this treatment does not actually restore the colon shortening. In addition, this inhibitory effect of Tacrolimus on increases in colon weight per unit length is more pronounced with 14-d than 7-d treatment, as shown by the inhibitory percentages (59% vs. 28%).

相關(guān)產(chǎn)品：Natural Product Library Plus  |  Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  Bioactive Compound Library Plus  |  Peptidomimetic Library  |  Macrocyclic Compound Library  |  Myricetin 3-O-α-L-arabinopyranoside  |  (1R,2S,7R)-Sitafloxacin-d₄ hydrochloride  |  Nebacumab  |  BN82002  |  Doxorubicin-¹³C,d₃ TFA  |  Gepotidacin  |  Rubrofusarin 6-O-β-D-glucopyranoside  |  Amycolatopsin A  |  Antibiotic A-33853  |  Estradiol hemihydrate  |  Sulbactam-d₂ sodium  |  Antimicrobial agent-5  |  NBTIs-IN-4  |  Proanthocyanidins  |  Anticancer agent 120  |  Azlocillin sodium salt  |  Antitubercular agent-13  |  Toyocamycin  |  Lenampicillin hydrochloride  |  Hispolon  |  PC58538  |  SPR206 acetate  |  Caracemide  |  Antimicrobial agent-10  |  Doxycycline calcium  |  Antibacterial agent 138  |  Staurosporine  |  Dihydrostreptomycin sulfate  |  Quorum Sensing-IN-2  |  Ciclopirox olamine

熱門(mén)產(chǎn)品線：重組蛋白  |  化合物庫(kù)  |  天然產(chǎn)物  |  熒光染料  |  PROTAC  |  同位素標(biāo)記物  |  寡核苷酸  |  抗體  |  點(diǎn)擊化學(xué)

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry